Probiogen Successfully Completes Research Collaboration for the Creation of a New Human Cell Line for Merck & Co., Inc.

07-Jun-2004

Berlin. ProBioGen AG today announced the successful completion of a research collaboration that resulted in the creation of a new human cell line for use by Merck & Co., Inc. The cell line has been designed for use by Merck in the production of biologicals such as vaccines, and may also be useful in the production of recombinant proteins.

The cell line is derived from a living healthy adult donor with a complete medical history who has fully consented to use of material for this purpose. ProBioGen created the cell line as part of an agreement with Merck that was signed in December 2001. Under the terms of the agreement, ProBioGen received a milestone payment for the delivery of the new cell line and is eligible for a further milestone payment based upon enhancing the properties of the cell line for use in development of biological products. ProBioGen would be eligible for royalty payments should these biological products be marketed.

"We are very proud to have successfully created this new cell line in such a short time despite the high risks involved in this field of research," said Michael Schlenk, CEO of ProBioGen. "This project has underpinned the calibre of our R&D team in specialized cell line development."

"We have enjoyed a stimulating interaction with ProBioGen in developing this new cell line and are pleased that the project has successfully met the challenging goals of the research collaboration," said John Shiver, Ph.D., vice president of vaccine and biologics research at Merck.

https://www.bionity.com/en/news/37917/probiogen-successfully-completes-research-collaboration-for-the-creation-of-a-new-human-cell-line-for-merck-co-inc.html